Lack of Better Infrastructure and Healthcare Facilities Dampens Adoption of Cytology and HPV Testing: Transparency Market Research

11 Jul, 2016, 13:00 ET from Transparency Market Research

ALBANY, New York, July 11, 2016 /PRNewswire/ --

The competitive landscapes of the cytology testing market and the human papillomavirus (HPV) testing market are both oligopolistic in nature. Transparency Market Research has found that a handful of large companies have been enjoying dominance over the global scenario, thereby reducing the level of competition and making the entry of new players extremely difficult.

Qiagen N.V., Hologic, Inc., and F.Hoffman-La Roche AG together enjoy a massive 86% of the HPV testing market. "Considering that the market shares of the first and second place companies catering to the demand for HPV testing are rather close, upcoming approvals for new screening tests are likely to have a significant impact on their position in the market," the author of the study states. For instance, the 2014 approval of Roche's cobas HPV test by the U.S. Food and Drug Administration (FDA) has resulted in the upsurge of the company's market share from what it was a couple of years ago.

You can download a sample for free: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2216

Similarly, Hologic and Becton Dickinson account for 89% of the cytology testing market. The only competition observed by TMR in this area of the market is currently in the segment of Pap tests in the U.S., which is a lucrative avenue for cytology testing. However, non-FDA approved tests also pose a threat to the present status of players.

"Companies in the overall cytology and HPV testing market have been relying on international expansions and collaborations to retain their dominance," the analyst states. Direct engagement with diagnostic laboratories and contracting with governments for patient care programs are also a few key strategies adopted by the players.

Disparate Levels of Awareness among Patients Regarding Cytology and HPV Testing 

The growing incidence of cervical cancer as well as HPV infections is the single most important factor driving the demand for cytology and HPV testing. The number of new cases of cervical cancer and the number of deaths resulting from this chronic condition have propelled patients to opt for early detection and diagnosis methods. The rise in awareness about the commercial availability of screening tests has driven the adoption of cytology testing. The high incidence rate of HPV infections and growing awareness regarding the threat that these infections pose to the immune system have fueled HPV testing and Pap smear screening.

However, TMR has observed that several emerging markets present a similar challenge. "The lack of access to better healthcare and infrastructure for women and the presence of outdated facilities in most developing countries restrict the large-scale adoption of cytology and HPV testing," the analyst states.

Browse research report with ToC & free analysis: http://www.transparencymarketresearch.com/cytology-hpv-testing-market.html

Cytology and HPV Testing Services to Continue Leading Streak 

The global market for cytology and HPV testing is projected to expand at a rapid pace over the coming years, with the value rising from US$7.9 bn in 2015 to US$10.5 bn by 2024. North America is the largest as well as the fastest expanding regional market in terms of revenue and this segment is poised to develop at a 3.3% CAGR during the forecast period to reach US$5.8 bn by 2024. While HPV testing services dominate the HPV testing market by revenue, assays kits are anticipated to register the highest CAGR of 10.1% from 2016 to 2024. On the other hand, the cytology testing market is led by cytology testing services and cytology testing assay kits are likely to expand at a 5.1% CAGR, the fastest among other sub-segments.

The key players in the global pharmacovigilance market, as described in the report, include Wipro Limited, Novartis International AG, GlaxoSmithKline Plc., Pharmaceutical Product Development, LLC, (PPD), F. Hoffmann-La Roche Ltd., Accenture Plc., Cognizant Technology Solutions, Covance, Inc., Quintiles Transnational Holdings, Inc., and PAREXEL International Corporation.

This review is based on the findings of a TMR report titled "Cytology and HPV Testing: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015-2023."

Global Cytology and HPV Testing Market, by Product and Services 

  • Cytology Testing
    • Systems
    • Assay Kits
    • Services
  • HPV Testing
    • Systems
    • Assay Kits
    • Services

Global Cytology and HPV Testing Market, by Geography 

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World (RoW)

Browse Other Latest Research Reports:  

About Us: 

Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact:
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
United States.
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Blog: http://www.tmrblog.com/

SOURCE Transparency Market Research